Clinical trial · Observational
Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC
A Multicenter, Prospective Real World Study on Recombinant Human Endostatin (Endostar) Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III Non-small-cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The chemoradiotherapy (CCRT) is still a standard treatment for the unresectabl stage III NSCLC.However, prognosis following this treatment is generally poor, with 5-year survival of 15-20%. The result of published HELPER study had showed that Endostar, a kind of angiogenesis agent, in combination with CCRT could improve the efficacy and safety. In order to verify the rusults, the investigators design the current study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Unresectable Stage III NSCLC | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- PFS
- timeFrame
- 15 months
- description
- progress free survival
Secondary outcomes (4)
- measure
- OS
- timeFrame
- 3 years
- description
- Overall survival
- measure
- LRFS
- timeFrame
- 2 years
- description
- Locoregional relapse-free survival
- measure
- DMFS
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * untreated pathologically confirmed inoperable stage III NSCLC according to the 8th edition of the American Joint Committee on Cancer staging system; * at least one measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)1.1; * 18-75 years of age; * Eastern Cooperative Oncology Group performance status score (ECOG PS) of 0 to 1; * 10\) FEV1\>1.0 L; * suitable function of bone marrow, liver, kidney and coagulation Exclusion Criteria: history of other malignant diseases, uncontrolled hypertension, any contraindications to chemoradiotherapy, pregnancy, breastfeeding or preexisting bleeding diatheses. \-
References
Publications (0)
Data not yet available